Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib

Abdulraheem Yacoub • 12 Jun 2020
EHA 2020
Myelofibrosis Myeloproliferative Neoplasms Parsaclisib Ruxolitinib

Abdulraheem Yacoub, MD, of the University of Kansas Medical Center, Kansas City, MO, discusses a Phase II study exploring the use of parsaclisib, a PI3Kdelta inhibitor in myelofibrosis patients that show suboptimal responses to ruxolitinib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Abdulraheem Yacoub

Current barriers to early intervention in myelofibrosis 1:58
Current barriers to early intervention in myelofibrosis
Abdulraheem Yacoub • 24 Aug 2024
The importance of early intervention in myelofibrosis 1:06
The importance of early intervention in myelofibrosis
Abdulraheem Yacoub • 24 Aug 2024
Final results of a Phase II study of add-on parsaclisib for pts with MF and suboptimal rux response 1:07
Final results of a Phase II study of add-on parsaclisib for pts with MF and suboptimal rux response
Abdulraheem Yacoub • 24 Aug 2024
The development of anti-fibrotic agents for treating myelofibrosis 2:00
The development of anti-fibrotic agents for treating myelofibrosis
Abdulraheem Yacoub • 24 Aug 2024

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals